Skip to content

Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder

CBT Augmentation of Paroxetine for Social Anxiety

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00074802
Enrollment
150
Registered
2003-12-22
Start date
2003-12-31
Completion date
2008-05-31
Last updated
2017-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social Anxiety Disorder

Keywords

Social Phobia

Brief summary

This study will examine whether the addition of cognitive behavioral therapy can improve the efficacy of the medication paroxetine (Paxil®) in treating individuals with social anxiety disorder. Patients with social anxiety disorder will undergo a 12-week open trial with paroxetine. Those who complete the open trial having achieved only partial response will be randomized to receive cognitive behavioral therapy (CBT) in addition to paroxetine or to continue on paroxetine alone for an additional 16 weeks.

Detailed description

Social anxiety disorder is a prevalent and disabling condition for which effective long-term treatments need to be identified. Paroxetine is effective in treating the acute symptoms of social anxiety, but many patients achieve less than optimal response. CBT has also been effective in treating social anxiety disorder; thus,it may also be effective in augmenting paroxetine response. This study will examine the effects of paroxetine treatment alone and in combination with CBT among patients who achieve less than optimal response after an open trial with paroxetine. Participants in this study will receive paroxetine for 12 weeks (Phase 1). After 12 weeks, participants who have completed this open trial but have achieved some but less than optimal response will move forward to Phase 2. To be eligible to move forward to Phase 2, patients must have achieved at least a 10% improvement in their open-trial Liebowitz Social Anxiety Scale Scores (LSAS) but still have an LSAS score of 30 or greater. Patients meeting these criteria will be randomly assigned to either add weekly sessions of CBT to their treatment or to continue taking paroxetine alone for another 16 weeks. Social anxiety symptoms, rates of response and remission, fear of negative evaluation, disability and quality of life will be assessed.

Interventions

DRUGParoxetine

Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.

BEHAVIORALCognitive behavioral therapy (CBT)

CBT will consist of 16 weekly treatment sessions.

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
Temple University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Independent evaluators were unaware of randomized condition in the augmentation phase (Phase 2).

Intervention model description

Open trial of paroxetine (Phase 1) followed by randomization to either continued paroxetine or continued paroxetine plus cognitive behavioral therapy (Phase 2) for patients showing partial response to paroxetine in Phase 1.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) criteria for generalized social phobia * Willing and able to give written informed consent * English-speaking

Exclusion criteria

* Prior or current diagnosis of schizophrenia, schizoaffective disorder, organic mental disorder, bipolar disorder, or antisocial, schizotypal, and schizoid personality disorders * Suicidal thoughts * History of failed paroxetine treatment of at least 6 weeks' duration at adequate doses or a history of failed outcome of a previous adequate trial of CBT * Clinically significant and/or unstable medical disease * Pregnancy or breast-feeding. Women of childbearing potential will be required to sign a statement indicating their intention to avoid pregnancy during the study through the use of an effective method of contraception. * Alcohol or substance abuse or dependence within the past 3 months. Patients with a positive drug screen but no substance abuse disorder will be eligible for the study, provided they have not met criteria for abuse/dependence within the last 6 months and provide two clean urine samples 2 weeks apart. * Current or past history of seizure disorder (except febrile seizure in childhood) * Conditions that contraindicate the use of paroxetine * Inability to tolerate or unwillingness to accept a drug-free period of 4 weeks for monoamine oxidase inhibitors (MAOIs) or fluoxetine and 2 weeks for other selective serotonin reuptake inhibitors (SSRIs), neuroleptics, antidepressants, benzodiazepines, mood stabilizers, buspirone, beta-adrenergic blockers, or other psychotropic drugs prior to beginning the study * Currently receiving psychotherapy

Design outcomes

Primary

MeasureTime frameDescription
Liebowitz Social Anxiety Scale (LSAS)Change measured from Week 12 to Week 28The LSAS is a 24-item clinician-administered measure, which provides 0-3 ratings for anxiety and avoidance of social and performance situations. Anxiety and avoidance ratings are summed across items, yielding a range of scores from 0-144, with higher scores representing greater severity of social anxiety symptoms. We examined amount of change from week 12 to week 28 as the primary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.

Secondary

MeasureTime frameDescription
Social Interaction Anxiety Scale (SIAS)Change measured from Week 12 to Week 28The SIAS is a 20-item self-report measure of anxiety experienced while interacting in dyads or groups. Items are rated on a 0-4 scale, yielding a range of scores from 0-80, with higher scores representing greater anxiety. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.
Social Phobia Scale (SPS)Change measured from Week 12 to Week 28The SPS is a 20-item self-report measure of anxiety experienced when being observed by others. Items are rated on a 0-4 scale, yielding a range of scores from 0-80, with higher scores representing greater anxiety. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.
Clinical Global Impression Improvement Scale (CGI-I)Responder and remitter status measured at Week 28The CGI-I is a 7-point clinician-administered scale measuring improvement in symptoms over time. Lower numbers represent greater improvement. We examined responder status (i.e., percent of patients receiving an endpoint, Week 28, rating of 1 or 2) as well as remission status (i.e., percent of patients receiving an endpoint, Week 28, rating of 1) as secondary outcomes.
Liebowitz Self-Report Disability Scale (LSRDS)Change measured from Week 12 to Week 28The LSRDS is an 11-item self-report measure of the degree to which one's emotional problems limit one's ability to function in a variety of domains. Items are rated on a 0-3 scale of severity, and 10 of the 11 items (choosing either school or work as one area and omitting the other) are summed to produce a total score, ranging from 0-30. Higher scores represent greater disability. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.
Quality of Life Inventory (QOLI)Change measured from Week 12 to Week 28The QOLI is a 16-item self-report measure of life satisfaction. Each item is rated for importance (0-2) and satisfaction (-3 to +3), and these ratings are multiplied, summed, and divided by the number of non-zero entries to yield an average item score, which can range from -6 to +6. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.
Brief Fear of Negative Evaluation Scale (BFNE)Change measured from Week 12 to Week 28The BFNE is a 12-item self-report measure of concern about negative evaluation by others. Items are rated on a 1-5 scale, yielding scores ranging from 12-60, with higher scores indicating greater fear of negative evaluation. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.

Countries

United States

Participant flow

Recruitment details

Recruitment began in 2003 at the Adult Anxiety Clinic of Temple University and the Anxiety Disorders Clinic of the New York State Psychiatric Institute. 150 patients with Generalized Social Anxiety Disorder were enrolled in Phase I of the study (open treatment with the selective serotonin reuptake inhibitor paroxetine).

Pre-assignment details

Among the 150 patients enrolled in Phase I, a total of 61 patients began Phase II These patients were classified as partial responders at week 12 (LSAS\>29 but at least 10% improvement in LSAS score), and were therefore randomized to receive 16 weeks of continued treatment with paroxetine with or without CBT.

Participants by arm

ArmCount
Paroxetine Continuation
Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine for 16 additional weeks. Paroxetine: Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
29
Paroxetine With CBT Augmentation
Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine plus cognitive behavioral therapy (CBT) for 16 additional weeks. Paroxetine: Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day. Cognitive behavioral therapy (CBT): CBT will consist of 16 weekly treatment sessions.
32
Total61

Baseline characteristics

CharacteristicParoxetine With CBT AugmentationTotalParoxetine Continuation
Age, Continuous32.22 years
STANDARD_DEVIATION 9.73
33.72 years
STANDARD_DEVIATION 11.05
35.38 years
STANDARD_DEVIATION 12.3
Brief Fear of Negative Evaluation Scale21.83 units on a scale
STANDARD_DEVIATION 6.41
23.82 units on a scale
STANDARD_DEVIATION 7.13
26.20 units on a scale
STANDARD_DEVIATION 7.34
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants7 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
28 Participants54 Participants26 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Liebowitz Self-Rated Disability Scale6.58 units on a scale
STANDARD_DEVIATION 4.4
7.42 units on a scale
STANDARD_DEVIATION 4.52
8.42 units on a scale
STANDARD_DEVIATION 4.56
Liebowitz Social Anxiety Scale44.63 units on a scale
STANDARD_DEVIATION 13.6
46.92 units on a scale
STANDARD_DEVIATION 16.55
49.45 units on a scale
STANDARD_DEVIATION 19.23
Quality of Life Inventory0.31 units on a scale
STANDARD_DEVIATION 1.67
0.48 units on a scale
STANDARD_DEVIATION 1.66
0.67 units on a scale
STANDARD_DEVIATION 1.65
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
8 Participants11 Participants3 Participants
Race (NIH/OMB)
Black or African American
4 Participants12 Participants8 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
5 Participants10 Participants5 Participants
Race (NIH/OMB)
White
15 Participants28 Participants13 Participants
Sex: Female, Male
Female
8 Participants18 Participants10 Participants
Sex: Female, Male
Male
24 Participants43 Participants19 Participants
Social Interaction Anxiety Scale35.43 units on a scale
STANDARD_DEVIATION 12.35
37.19 units on a scale
STANDARD_DEVIATION 11.85
39.30 units on a scale
STANDARD_DEVIATION 11.08
Social Phobia Scale17.43 units on a scale
STANDARD_DEVIATION 10.85
18.62 units on a scale
STANDARD_DEVIATION 11.29
20.04 units on a scale
STANDARD_DEVIATION 11.87

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 290 / 32
other
Total, other adverse events
29 / 2929 / 32
serious
Total, serious adverse events
1 / 290 / 32

Outcome results

Primary

Liebowitz Social Anxiety Scale (LSAS)

The LSAS is a 24-item clinician-administered measure, which provides 0-3 ratings for anxiety and avoidance of social and performance situations. Anxiety and avoidance ratings are summed across items, yielding a range of scores from 0-144, with higher scores representing greater severity of social anxiety symptoms. We examined amount of change from week 12 to week 28 as the primary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.

Time frame: Change measured from Week 12 to Week 28

Population: Data analysis was conducted via mixed-effects linear regression which allows use of data from patients with missing observations by using maximum likelihood estimation. The same holds true for all continuous outcome measures. However, mean change (and SDs) reported here is based on completed observations.

ArmMeasureValue (MEAN)Dispersion
Paroxetine ContinuationLiebowitz Social Anxiety Scale (LSAS)7.77 units on a scaleStandard Deviation 22.49
Paroxetine With CBT AugmentationLiebowitz Social Anxiety Scale (LSAS)7.84 units on a scaleStandard Deviation 17.15
p-value: 0.26795% CI: [-15.05, 4.19]Mixed Models Analysis
Secondary

Brief Fear of Negative Evaluation Scale (BFNE)

The BFNE is a 12-item self-report measure of concern about negative evaluation by others. Items are rated on a 1-5 scale, yielding scores ranging from 12-60, with higher scores indicating greater fear of negative evaluation. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.

Time frame: Change measured from Week 12 to Week 28

Population: Data analysis was conducted via mixed-effects linear regression which allows use of data from patients with missing observations by using maximum likelihood estimation. The same holds true for all continuous outcome measures. However, mean change (and SDs) reported here is based on completed observations.

ArmMeasureValue (MEAN)Dispersion
Paroxetine ContinuationBrief Fear of Negative Evaluation Scale (BFNE)1.13 units on a scaleStandard Deviation 4.59
Paroxetine With CBT AugmentationBrief Fear of Negative Evaluation Scale (BFNE)3.91 units on a scaleStandard Deviation 5.69
p-value: 0.000695% CI: [-8.7, -2.35]Mixed Models Analysis
Secondary

Clinical Global Impression Improvement Scale (CGI-I)

The CGI-I is a 7-point clinician-administered scale measuring improvement in symptoms over time. Lower numbers represent greater improvement. We examined responder status (i.e., percent of patients receiving an endpoint, Week 28, rating of 1 or 2) as well as remission status (i.e., percent of patients receiving an endpoint, Week 28, rating of 1) as secondary outcomes.

Time frame: Responder and remitter status measured at Week 28

Population: Responders (CGI-I=1 or 2). Remitters (CGI-I=1). Analyses based on Week 28 observations if available. if not, Week 20 or Week 12 observations were substituted. Fisher's Exact Test used for analyses.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Paroxetine ContinuationClinical Global Impression Improvement Scale (CGI-I)Responder StatusResponder17 Participants
Paroxetine ContinuationClinical Global Impression Improvement Scale (CGI-I)Responder StatusNon-Responder12 Participants
Paroxetine ContinuationClinical Global Impression Improvement Scale (CGI-I)Remitter StatusResponder3 Participants
Paroxetine ContinuationClinical Global Impression Improvement Scale (CGI-I)Remitter StatusNon-Responder26 Participants
Paroxetine With CBT AugmentationClinical Global Impression Improvement Scale (CGI-I)Remitter StatusNon-Responder21 Participants
Paroxetine With CBT AugmentationClinical Global Impression Improvement Scale (CGI-I)Responder StatusResponder28 Participants
Paroxetine With CBT AugmentationClinical Global Impression Improvement Scale (CGI-I)Remitter StatusResponder11 Participants
Paroxetine With CBT AugmentationClinical Global Impression Improvement Scale (CGI-I)Responder StatusNon-Responder4 Participants
Comparison: Fisher's Exact Test used for analyses of responder status.p-value: 0.018Fisher Exact
Comparison: Fisher's Exact Test used for analyses of remitter status.p-value: 0.034Fisher Exact
Secondary

Liebowitz Self-Report Disability Scale (LSRDS)

The LSRDS is an 11-item self-report measure of the degree to which one's emotional problems limit one's ability to function in a variety of domains. Items are rated on a 0-3 scale of severity, and 10 of the 11 items (choosing either school or work as one area and omitting the other) are summed to produce a total score, ranging from 0-30. Higher scores represent greater disability. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.

Time frame: Change measured from Week 12 to Week 28

Population: Data analysis was conducted via mixed-effects linear regression which allows use of data from patients with missing observations by using maximum likelihood estimation. The same holds true for all continuous outcome measures. However, mean change (and SDs) reported here is based on completed observations.

ArmMeasureValue (MEAN)Dispersion
Paroxetine ContinuationLiebowitz Self-Report Disability Scale (LSRDS)1.25 units on a scaleStandard Deviation 3.3
Paroxetine With CBT AugmentationLiebowitz Self-Report Disability Scale (LSRDS)-0.02 units on a scaleStandard Deviation 2.72
p-value: 0.87195% CI: [-2.16, 2.55]Mixed Models Analysis
Secondary

Quality of Life Inventory (QOLI)

The QOLI is a 16-item self-report measure of life satisfaction. Each item is rated for importance (0-2) and satisfaction (-3 to +3), and these ratings are multiplied, summed, and divided by the number of non-zero entries to yield an average item score, which can range from -6 to +6. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.

Time frame: Change measured from Week 12 to Week 28

Population: Data analysis was conducted via mixed-effects linear regression which allows use of data from patients with missing observations by using maximum likelihood estimation. The same holds true for all continuous outcome measures. However, mean change (and SDs) reported here is based on completed observations.

ArmMeasureValue (MEAN)Dispersion
Paroxetine ContinuationQuality of Life Inventory (QOLI)0.25 units on a scaleStandard Deviation 1.24
Paroxetine With CBT AugmentationQuality of Life Inventory (QOLI)-0.35 units on a scaleStandard Deviation 1.72
p-value: 0.94995% CI: [-11.95, 12.76]Mixed Models Analysis
Secondary

Social Interaction Anxiety Scale (SIAS)

The SIAS is a 20-item self-report measure of anxiety experienced while interacting in dyads or groups. Items are rated on a 0-4 scale, yielding a range of scores from 0-80, with higher scores representing greater anxiety. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.

Time frame: Change measured from Week 12 to Week 28

Population: Data analysis was conducted via mixed-effects linear regression which allows use of data from patients with missing observations by using maximum likelihood estimation. The same holds true for all continuous outcome measures. However, mean change (and SDs) reported here is based on completed observations.

ArmMeasureValue (MEAN)Dispersion
Paroxetine ContinuationSocial Interaction Anxiety Scale (SIAS)3.43 units on a scaleStandard Deviation 9.58
Paroxetine With CBT AugmentationSocial Interaction Anxiety Scale (SIAS)5.67 units on a scaleStandard Deviation 11.55
p-value: 0.000595% CI: [-5.02, -1.39]Mixed Models Analysis
Secondary

Social Phobia Scale (SPS)

The SPS is a 20-item self-report measure of anxiety experienced when being observed by others. Items are rated on a 0-4 scale, yielding a range of scores from 0-80, with higher scores representing greater anxiety. We examined amount of change at from week 12 to week 28 as a secondary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive change.

Time frame: Change measured from Week 12 to Week 28

Population: Data analysis was conducted via mixed-effects linear regression which allows use of data from patients with missing observations by using maximum likelihood estimation. The same holds true for all continuous outcome measures. However, mean change (and SDs) reported here is based on completed observations.

ArmMeasureValue (MEAN)Dispersion
Paroxetine ContinuationSocial Phobia Scale (SPS)2.75 units on a scaleStandard Deviation 10.29
Paroxetine With CBT AugmentationSocial Phobia Scale (SPS)5.83 units on a scaleStandard Deviation 8.59
p-value: 0.077595% CI: [-11.84, 0.62]Mixed Models Analysis

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026